Revenue
2011
2012
2013
2016
2017
2018
2020
2021
2022
2023
2024
2025
2026
Vistagen Therapeutics, Inc. (VTGN)
Price$0.2428Cached quote
Net income
1999
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Free cash flow
2011
2012
2013
2014
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Total cash / debt
CashTotal debt
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.3M | $486,000 | $1.1M | −$227,000 | $1.1M | $1.1M | $0 | — | $0 | $1.3M | $0 | — | — | $200,400 | $1.3M | $2.1M | — | — | — | — | — | — | — | — | — | — | — | — |
| Research & development | $55.0M | $39.4M | $20.0M | $44.4M | $35.4M | $11.9M | $13.4M | $17.1M | $7.8M | $5.2M | $3.9M | $2.4M | $2.5M | $3.4M | $5.4M | $3.7M | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $73.4M | $56.5M | $34.1M | $59.0M | $48.9M | $19.0M | $20.8M | $24.6M | $14.2M | $11.5M | $17.9M | $6.8M | $5.0M | $7.0M | $10.4M | $8.6M | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | −$72.1M | −$56.0M | −$33.0M | −$59.3M | −$47.8M | −$17.9M | −$20.8M | −$24.6M | −$14.2M | −$10.2M | −$17.9M | −$6.8M | −$5.0M | −$6.8M | −$9.0M | −$6.6M | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −5,683.69% | −11,517.08% | −3,103.48% | — | −4,308.68% | −1,646.06% | — | — | — | −819.88% | — | — | — | −3,389.77% | −673.77% | −316.99% | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA | −$71.9M | −$55.8M | −$32.9M | −$59.1M | −$47.6M | −$17.8M | −$20.7M | −$24.5M | −$14.1M | −$10.2M | −$17.8M | −$6.7M | −$5.0M | −$6.8M | −$9.0M | −$6.5M | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA margin | −5,668.01% | −11,486.21% | −3,091.54% | — | −4,294.83% | −1,635.26% | — | — | — | −815.49% | — | — | — | −3,372.90% | −670.38% | −314.80% | — | — | — | — | — | — | — | — | — | — | — | — |
| Net income | −$69.7M | −$51.4M | −$29.4M | −$59.2M | −$47.8M | −$17.9M | −$20.8M | −$24.6M | −$14.3M | −$10.3M | −$47.2M | −$13.9M | −$3.0M | −$12.9M | −$12.2M | −$9.5M | −$4.1M | −$4.7M | −$5.4M | −$2.0M | −$1.8M | −$1.1M | −$8.8M | −$502,600 | −$2.1M | −$1.8M | −$700,000 | −$230,900 |
| Net profit margin | −5,491.33% | −10,579.84% | −2,759.59% | — | −4,307.19% | −1,646.09% | — | — | — | −820.44% | — | — | — | −6,430.49% | −909.66% | −457.86% | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic EPSper basic share | -$1.83 | -$1.67 | -$1.52 | -$8.51 | -$7.38 | -$14.71 | -$15.02 | -$27.03 | -$33.63 | -$46.25 | -$873.27 | -$316.22 | -$81.08 | -$38.14 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPSper diluted share | -$1.83 | -$1.67 | -$1.52 | -$8.51 | — | -$14.71 | -$15.02 | -$27.03 | -$33.63 | -$46.25 | -$873.27 | -$318.62 | -$114.41 | -$38.14 | -$24.92 | -$54.35 | — | — | — | — | — | — | — | — | — | — | — | — |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
Commodore Capital LP | 2.79M |
VANGUARD CAPITAL MANAGEMENT LLC | 1.57M |
TWO SIGMA INVESTMENTS, LP | 847.99K |
ACADIAN ASSET MANAGEMENT LLC | 794.58K |
RENAISSANCE TECHNOLOGIES LLC | 730.5K |
STEMPOINT CAPITAL LP | 616.75K |
Ikarian Capital, LLC | 519.08K |
AdvisorShares Investments LLC | 438.64K |
LUMINUS MANAGEMENT LLC | 403.12K |
GEODE CAPITAL MANAGEMENT, LLC | 365K |
ADAR1 Capital Management, LLC | 351.14K |
BlackRock, Inc. | 345.43K |
GROUP ONE TRADING LLC | 304.39K |
Verdad Advisers, LP | 293.34K |
VANGUARD FIDUCIARY TRUST CO | 217.7K |
JANE STREET GROUP, LLC | 164.83K |
BOOTHBAY FUND MANAGEMENT, LLC | 134.57K |
STATE STREET CORP | 121.11K |
XTX Topco Ltd | 118.38K |
NORTHERN TRUST CORP | 80.82K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data